Immunotherapy Shows Promise in Reducing the Risk Of Lung Cancer Relapse After Surgery

by: cancercompass

The results of a long-term clinical trial on MAGE-A3 AASCI (Antigen-Specific Cancer Immunotherapeutic) presented at the 1st European Lung Cancer Conference, on behalf of the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO), showed that this immune-boosting treatment for lung cancer patients reduces the risk of relapse after surgery, to the same extent as chemotherapy.

The article, available at the European Society for Medical Oncology describes the results of a 44 month follow up from a double-blind placebo-controlled trial of 182 cancer patients with non-small cell lung cancer.

The trial randomly selected lung cancer patients, after complete surgical resection of the tumor, to receive either placebo injections or injections of MAGE-A3 ASCI administered over the course of 27 months. 44 months later, 69 of the 182 patients included in the trial experienced a recurrence of their cancer. The lung cancer patients that were given the MAGE-A3 AASCI injections were less likely to have recurrences, had more time before their lung cancer recurred, and were less likely to die.

According to the ESMO, Phase III of the therapy trial, named MAGRIT, has begun.